Cover Image
市場調查報告書

全球OTC腸胃藥

Global OTC Gastrointestinals

出版商 Nicholas Hall & Company 商品編碼 320884
出版日期 內容資訊 英文 325 Pages
訂單完成後即時交付
價格
Back to Top
全球OTC腸胃藥 Global OTC Gastrointestinals
出版日期: 2015年03月02日 內容資訊: 英文 325 Pages
簡介

全球OTC腸胃藥銷售額2014年達到160億美元,構成OTC藥整體12%。成長持續受自有品牌競爭的影響,不過,交換活動與創新帶來2014年第2季的業績改善。

本報告提供全球OTC腸胃藥市場相關調查分析、消費者趨勢、各分類的分析、法規情形、品牌的案例研究,及今後的產業展望等彙整資料,為您概述為以下內容。

主要的調查內容

全球腸胃藥 (GI) 概要

  • 消費者趨勢,全球類別分析等

主要GI市場

  • 主要趨勢,各分類分析,支撐法規的發展,主要區分與品牌的成功因素,以及未來預測

品牌的案例研究

  • NoSpa、Pepcid AC、Prevacid 及Nexium 24HR

GI的展望

  • 全球GI產業的展望,各市場上機會、威脅、銷售額預測

調查對象分類

  • 解酸劑
  • 腸胃藥
  • 瀉藥
  • 定位在GI的益生菌
  • 肝臟 & 膽汁治療藥
  • 腹瀉決定性的一擊藥
  • 制嘔吐劑
  • 消化酵素
  • 止痙攣藥 & IBS治療藥
  • 傳統胃腸藥

調查對象國家

  • 巴西
  • 加拿大
  • 中國
  • 法國
  • 德國
  • 印度
  • 義大利
  • 日本
  • 墨西哥
  • 波蘭
  • 俄羅斯
  • 韓國
  • 西班牙
  • 英國
  • 美國
目錄

OTC GIs sales reached almost $16bn in the year to mid-2014 - a 12% slice of the global OTC pie. Although growth continued to be impacted by private label competition, an improved Q2 2014 performance resulted from switch activity and innovation. The large US antacids category was revived by the May 2014 launch of PPI brand Nexium 24HR. In many markets format innovation that improves convenience, such as thin films, gummies and on-the-go sachets, contributed to growth.

Increasing consumer awareness, mass market expansion and changing lifestyle habits boosted sales in Asia-Pacific, the largest region for GIs globally. China and India stood out in growth terms, but most markets expanded in 2014. Europe experienced mixed fortunes: C&EE boasted one of the strongest performances of all regions, helped by exceptional growth of liver & bile remedies in Russia, while Western Europe flatlined, with collapsing sales in France offsetting modest growth in other markets. Latin America continues to set the benchmark for high growth, with all countries and categories recording healthy rises.

Discover all there is to know about OTC Gastrointestinals with Nicholas Hall's upcoming report, which contains multi-country coverage and detailed reporting of individual categories and brands. Incorporating OTC sales to mid-2014 from Nicholas Hall's Global OTC Database DB6, the report features the latest trends & developments, in-depth brand case studies, and vital insight into factors affecting individual markets and categories.

Key Questions Answered

  • What impact has been made so far by the numerous PPI launches around the globe? Can Nexium be a success in the US, Europe and Australia following switch?
  • Which strategies will marketers of brands adopt in countries where private labels and generics hinder growth?
  • Can GIs maintain their booming sales in Russia relying on a combination of price rises and high levels of A+P support?
  • How have changing lifestyle habits and increased consumer education contributed to strong growth in Asia-Pacific?
  • What launches and line extensions have been the main growth drivers in Latin America?
  • How will changing consumer demands alter marketers' strategies?

CATEGORIES COVERED IN THIS REPORT

  • Antacids
  • Antiflatulents
  • Laxatives
  • GI-positioned probiotics
  • Liver & bile remedies
  • Antidiarrhoeals
  • Antinauseants
  • Digestive enzymes
  • Antispasmodics & IBS remedies
  • Traditional digestive remedies

15 COUNTRIES PROFILED

  • Brazil
  • Canada
  • China
  • France
  • Germany
  • India
  • Italy
  • Japan
  • Mexico
  • Poland
  • Russia
  • S Korea
  • Spain
  • UK
  • USA

Table of Contents

Executive summary

Leading GIs markets

  • Brazil
    • Overview
    • Antacids
    • Laxatives
    • Liver & bile remedies
    • Antiflatulents
    • Antidiarrhoeals
    • Antispasmodics & IBS remedies
    • Probiotics
    • GIs outlook
  • Canada
    • Overview
    • Antacids
    • Laxatives
    • Antidiarrhoeals
    • Antinauseants
    • Digestive enzymes
    • Antiflatulents
    • Probiotics
    • GIs outlook
  • China
    • Overview
    • Antacids
    • Antinauseants
    • Laxatives
    • Liver & bile remedies
    • Antidiarrhoeals
    • Other gastrointestinals
    • Probiotics
    • GIs outlook
  • France
    • Overview
    • Laxatives
    • Antispasmodics & IBS remedies
    • Antidiarrhoeals
    • Antacids
    • Liver & bile remedies
    • Digestive enzymes
    • Antiflatulents
    • Antinauseants
    • Probiotics
    • GIs outlook
  • Germany
    • Overview
    • Laxatives
    • Antacids
    • Digestive enzymes
    • Liver & bile remedies
    • Antidiarrhoeals
    • Antinauseants
    • Antiflatulents
    • Probiotics
    • GIs outlook
  • India
    • Overview
    • Antacids
    • Traditional digestive remedies
    • Laxatives
    • Liver & bile remedies
    • Antidiarrhoeals
    • Probiotics
    • GIs outlook
  • Italy
    • Overview
    • Laxatives
    • Antacids
    • Antiflatulents
    • Antidiarrhoeals
    • Liver & bile remedies
    • Antispasmodics & IBS remedies
    • Antinauseants
    • Digestive enzymes
    • Probiotics
    • GIs outlook
  • Japan
    • Overview
    • Antacids
    • Laxatives
    • Antidiarrhoeals
    • Traditional digestive remedies
    • Antinauseants
    • Probiotics
    • GIs outlook
  • Mexico
    • Overview
    • Antacids
    • Antidiarrhoeals
    • Antispasmodics & IBS remedies
    • Laxatives
    • Probiotics
    • GIs outlook
  • Poland
    • Overview
    • Liver & bile remedies
    • Antacids
    • Laxatives
    • Antispasmodics & IBS remedies
    • Antidiarrhoeals
    • Antiflatulents
    • Probiotics
    • GIs outlook
  • Russia
    • Overview
    • Liver & bile remedies
    • Antacids
    • Antidiarrhoeals
    • Digestive enzymes
    • Laxatives
    • Antispasmodics & IBS remedies
    • Antiflatulents
    • Antinauseants
    • Probiotics
    • GIs outlook
  • South Korea
    • Overview
    • Liver & bile remedies
    • Antacids
    • Laxatives
    • Traditional digestive remedies
    • Digestive enzymes
    • Antidiarrhoeals
    • Probiotics
    • GIs outlook
  • Spain
    • Overview
    • Laxatives
    • Antacids
    • Antiflatulents
    • Antidiarrhoeals
    • Antispasmodics & IBS remedies
    • Liver & bile remedies
    • Antinauseants
    • Digestive enzymes
    • Probiotics
    • GIs outlook
  • UK
    • Overview
    • Antacids
    • Laxatives
    • Antidiarrhoeals
    • Antispasmodics & IBS remedies
    • Digestive enzymes
    • Antiflatulents
    • Antinauseants
    • Probiotics
    • GIs outlook
  • USA
  • Overview
    • Antacids
    • Laxatives
    • Antidiarrhoeals
    • Antiflatulents
    • Digestive enzymes
    • Antinauseants
    • Probiotics
    • GIs outlook
  • GIs brand case studies
    • Alka-Seltzer
    • Bifiform
    • Buscopan
    • Eno
    • Enterogermina
    • Essentiale
    • Iberogast
    • Lax-A-Day
    • Linex
    • Nexium 24HR
    • NoSpa
    • Pepcid AC
    • Prevacid 24HR
    • Tums
    • Zegerid OTC
  • Global outlook for GIs
Back to Top